XML 24 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Net revenues $ 37,867,945 $ 39,552,507
Costs and expenses:    
Cost of products sold 6,585,972 6,066,611
Selling and marketing 17,023,023 18,451,765
Research and development 4,816,206 5,834,229
General and administrative 11,126,901 10,651,915
Amortization and impairment 4,748,252 8,102,648
Total costs and expenses 44,300,354 49,107,168
Operating loss (6,432,409) (9,554,661)
Interest income 334,444 286,854
Other income 0 2,828,871
Other income - settlement 0 475,000
Other income - gain on insurance proceeds 237,089 346,800
Interest expense (605,508) (667,861)
Loss before income taxes (6,466,384) (6,284,997)
Income tax benefit (expense) 22,669 (45,769)
Net loss (6,443,715) (6,330,766)
Net (income) loss at subsidiary attributable to noncontrolling interests (36,055) 51,446
Net loss attributable to common shareholders $ (6,479,770) $ (6,279,320)
Loss per share attributable to common shareholders:    
Basic (in USD per share) $ (0.46) $ (0.44)
Diluted (in USD per share) $ (0.46) $ (0.44)
Weighted-average shares outstanding    
Basic (in shares) 14,060,272 14,298,774
Diluted (in shares) 14,060,272 14,298,774
Product    
Net revenues $ 36,537,704 $ 37,513,492
Other    
Net revenues $ 1,330,241 $ 2,039,015